In a typical adult with alcohol use disorder who is not taking opioids and has no severe liver disease, which medication is preferred, naltrexone or acamprosate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Naltrexone vs Acamprosate for Alcohol Use Disorder

In a typical adult with alcohol use disorder who is not taking opioids and has no severe liver disease, acamprosate is preferred over naltrexone as first-line pharmacotherapy due to its superior safety profile, lack of hepatotoxicity, and comparable efficacy in maintaining abstinence.

Rationale for Acamprosate as First-Line

The 2020 AASLD guidelines explicitly note that acamprosate has no hepatic metabolism and no reported instances of hepatotoxicity, while naltrexone undergoes hepatic metabolism and has documented hepatocellular injury concerns 1. This distinction is critical even in patients without severe liver disease, as many individuals with AUD have subclinical hepatic impairment.

Efficacy Considerations

Both medications are FDA-approved and effective, but their mechanisms differ:

  • Acamprosate (666 mg three times daily) works as an NMDA receptor antagonist, reducing withdrawal symptoms and craving. The number needed to treat (NNT) to prevent return to any drinking is 11 1, 2
  • Naltrexone (50 mg daily) is an opioid receptor antagonist that reduces heavy drinking and craving. The NNT is 18 for preventing return to any drinking and 11 for preventing return to heavy drinking 1, 2

A 2023 JAMA meta-analysis of 118 trials found both medications effective when combined with psychosocial interventions 2. However, a 2013 meta-analysis revealed nuanced differences: acamprosate demonstrates slightly larger effect sizes for maintaining abstinence, while naltrexone shows larger effects for reducing heavy drinking 3.

Clinical Decision Algorithm

For patients prioritizing complete abstinence:

  • Start acamprosate 666 mg three times daily
  • Requires prior detoxification and abstinence at treatment initiation for optimal effect 3
  • Continue for at least 12 months with psychosocial support 4

For patients with harm reduction goals (controlled drinking):

  • Naltrexone 50 mg daily may be considered if liver function is completely normal
  • Monitor liver enzymes closely (baseline, 1 month, then quarterly)
  • Requires abstinence for several days before initiation for better outcomes 3

Critical contraindications:

  • Naltrexone is absolutely contraindicated if patient is taking opioids (will precipitate withdrawal) 5
  • Acamprosate is contraindicated in severe renal impairment (CrCl ≤30 mL/min) 6

Safety Profile Comparison

Acamprosate:

  • Renally excreted, no hepatic metabolism 6
  • Main side effect: diarrhea (risk ratio 1.58 vs placebo) 2
  • Excellent safety profile in liver disease 1
  • Better medication compliance (OR 1.29) 7

Naltrexone:

  • Hepatically metabolized with documented hepatotoxicity risk 4, 1
  • Common side effects: nausea (RR 1.73), vomiting (RR 1.53) 2
  • Not studied in patients with alcohol-associated liver disease 1
  • Higher dropout rates due to side effects 8

Common Pitfalls to Avoid

  1. Starting naltrexone without checking liver enzymes: Always obtain baseline AST, ALT, bilirubin, and INR before initiating naltrexone
  2. Prescribing naltrexone to patients on opioids: This includes tramadol, codeine, and buprenorphine—verify opioid-free status
  3. Failing to require detoxification before acamprosate: Acamprosate is ineffective in patients who haven't achieved initial abstinence 4, 6
  4. Inadequate psychosocial support: Both medications require concurrent counseling for optimal outcomes 4, 9
  5. Premature discontinuation after relapse: Advise patients to continue medication even if they drink, and discuss relapse with provider 6

Evidence Quality

The 2020 AASLD guidelines provide the most recent authoritative guidance 1. The 2010 Hepatology guidelines established that both medications "may be considered" with Class I, Level A evidence 4, but the 2020 update emphasizes acamprosate's superior safety profile in the ALD population. The 2023 JAMA meta-analysis of 118 trials provides the highest-quality comparative efficacy data 2.

Bottom line: Acamprosate is the safer first-line choice for typical AUD patients due to its lack of hepatotoxicity, comparable efficacy, and better tolerability, with naltrexone reserved for specific clinical scenarios where harm reduction is the primary goal and liver function is definitively normal.

References

4
Guideline

alcoholic liver disease.

Hepatology, 2010

Related Questions

In a 48-year-old hypertensive man who drinks 2–3 martinis nightly to fall asleep, has binge‑drinking behavior, cannot reduce intake, and has a normal physical exam, which is the preferred treatment: acamprosate, disulfiram, naltrexone, or referral to a 12‑step program?
What is the difference in craving relief between acamprosate (Campral) and naltrexone for alcohol use disorder?
For an adult with alcohol use disorder and liver impairment who wishes to maintain abstinence, should acamprosate or naltrexone be used?
What is the recommended treatment approach for alcohol use disorder, including medically supervised detoxification, pharmacologic options (e.g., naltrexone, disulfiram, acamprosate) and psychosocial therapies?
Is combining acamprosate and naltrexone effective for improving abstinence rates in a patient with alcohol dependence?
What questions should I ask the oncologist about my relative's IDH‑wild‑type glioma, including confirmation of histologic grade and molecular profile, the recommended treatment plan (surgery, radiation, temozolomide), potential side effects, and the referral process to the Mayo Clinic?
In a 7-year-old child presenting with tachycardia (heart rate 130 bpm), fever 99 °F, tachypnea (respiratory rate 28/min), generalized body aches, vomiting, and pallor, what is the appropriate urgent management?
Can topiramate cause tongue swelling as part of an angio‑edema reaction?
Can Vyvanse (lisdexamfetamine) cause acne or other skin issues?
Can you interpret the laboratory results, including the complete blood count, for a 69‑year‑old woman with stage 3 chronic kidney disease, diabetes mellitus, hypothyroidism, and recurrent urinary‑tract infections?
How should I manage an adult patient presenting with 3–4 days of insomnia and persistent hiccups?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.